Merck relaunches customer collaboration centers with new concept and M Lab name
Enables explorations of new technologies and solutions to address development and manufacturing challenges.
Merck is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges, helping accelerate development of new therapies.
Formerly known as biomanufacturing science training centers, the new state-of-the-art M Lab concept will include a simulated manufacturing environment that provides customers a setting that fosters education and full end-to-end development support. The centers are created especially for customer collaboration in which problem solving for processing issues take place. Customers participate in product demonstrations, hands-on training and experiments, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer.
"We are the only company that offers full end-to-end process training, and we do it side-by-side with our customers, working together to solve critical challenges," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Now reimagined and reengineered as M Lab Collaboration Centers, Merck has taken its industry-leading concept to the next level by creating unique and inspiring settings where customers can explore new ways to increase productivity and improve processes in close collaboration Merck's team of experts.
"These centers have been an important resource for our customers and the biopharma industry for more than two decades and will continue to be important as we grow," Batra added.
Merck unveiled its first remodeled center in Tokyo, Japan on 29 June 2016. The network, established in 1995, will also include locations in Brazil, China, France, India, Singapore, South Korea and the United States. Formal relaunch of these centers will take place throughout the remainder of 2016 and 2017 with openings of the new M Lab concept in France, India, China, South Korea and the US.
Each center will welcome customers, collaborators from government, academia, regulatory bodies and industry associations, offering application best practices and knowledge sharing tailored to address the specific needs of the local biomanufacturing industry. Customers will have access to sizing and simulation tools and methodologies as well as analytical and modeling support. Hands-on and classroom-style training sessions and education programs are also provided.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance